RESUMO Atualmente não há tratamento curativo para as demências neurodegenerativas ou para a demência vascular, mas algumas intervenções farmacológicas e não farmacológicas podem contribuir para aliviar os sintomas, retardar a progressão da doença e melhorar a qualidade de vida. As abordagens terapêuticas atuais são baseadas na etiologia, no perfil dos sintomas e no estágio da demência. Neste artigo apresentamos recomendações sobre os tratamentos farmacológicos e não farmacológicos da demência devida à doença de Alzheimer, comprometimento cognitivo vascular, demência frontotemporal, demência da doença de Parkinson e demência com corpos de Lewy.

/pdf/tratamento-da-demencia-recomendacoes-do-departamento-9f0mtyv8.pdf

Tratamento da demência: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia

ABSTRACT There is currently no cure for neurodegenerative or vascular dementias, but some pharmacological and non-pharmacological interventions may contribute to alleviate symptoms, slow disease progression and improve quality of life. Current treatment approaches are based on etiology, symptom profile and stage of dementia. This manuscript presents recommendations on pharmacological and non-pharmacological treatments of dementia due to Alzheimer’s disease, vascular cognitive impairment, frontotemporal dementia, Parkinson’s disease dementia, and dementia with Lewy bodies. 

Treatment of dementia: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology

Cannabinoids are ligands that are either plant derived, synthetic, or semisynthetic, and have affinity for and activity at cannabinoid receptors. The biological effects of phytocannabinoids or synthetic cannabinoids, like endogenous cannabinoids, occur through interactions with the endocannabinoid system (ECS). This system is essential for a diverse range of brain functions including mood balance, energy balance, learning and memory and has been implicated in multiple psychiatric, neurological, neurodegenerative, and neuroinflammatory related diseases. The increasing societal and medical interest in the recreational and therapeutic use of cannabinoid drugs raises concern for unwanted adverse effects of exposure during critical life-stages or over the long-term as occurs with modification of the endocannabinoid system. Understanding the role of the ECS in various aspects of brain development and function is a critical basis for understanding the potential for adverse effects of usage on the nervous system upon recreational usage or therapeutic intervention. This chapter presents a background on the ECS and how interactions with this system may alter nervous system function. It presents information on the role of two mechanistic targets of the ECS, the GABAergic neurotransmitter system and the brain immune cell and considers how knowledge of these systems can advance our understanding of the effects of cannabinoids on the nervous system. 

Cannabinoids

ABSTRACT There is currently no cure for neurodegenerative or vascular dementias, but some pharmacological and non-pharmacological interventions may contribute to alleviate symptoms, slow disease progression and improve quality of life. Current treatment approaches are based on etiology, symptom profile and stage of dementia. This manuscript presents recommendations on pharmacological and non-pharmacological treatments of dementia due to Alzheimer’s disease, vascular cognitive impairment, frontotemporal dementia, Parkinson’s disease dementia, and dementia with Lewy bodies.

https://www.scielo.br/j/dn/a/qCcZ73tZ9Y9N93w7QngSWCq/?format=pdf&lang=pt

Cannabinoids comprehend endocannabinoids, phytocannabinoids, and synthetic cannabinoids, with actions both in the central and peripherical nervous systems. A considerable amount of publications have been made in recent years, although cannabis has been known for over a thousand years. Scientific Departments from the Brazilian Academy of Neurology described evidence for medical use in their areas. Literature is constantly changing, and possible new evidence can emerge in the next days or months. Prescription of these substances must be discussed with patients and their families, with knowledge about adverse events and their efficacy.

https://www.arquivosdeneuropsiquiatria.org/wp-content/uploads/articles_xml/1678-4227-anp-79-04-354/1678-4227-anp-79-04-354.pdf

Matheus Vale

Papers

Cannabinoids in Neurology - Position paper from Scientific Departments from Brazilian Academy of Neurology.